Comprehensive quantification of fuel use by the failing and nonfailing human heart

Danielle Murashige, Cholsoon Jang, Michael Neinast, Jonathan J Edwards, Alexis Cowan, Matthew C Hyman, Joshua D Rabinowitz, David S Frankel, Zolt Arany, Danielle Murashige, Cholsoon Jang, Michael Neinast, Jonathan J Edwards, Alexis Cowan, Matthew C Hyman, Joshua D Rabinowitz, David S Frankel, Zolt Arany

Abstract

The heart consumes circulating nutrients to fuel lifelong contraction, but a comprehensive mapping of human cardiac fuel use is lacking. We used metabolomics on blood from artery, coronary sinus, and femoral vein in 110 patients with or without heart failure to quantify the uptake and release of 277 metabolites, including all major nutrients, by the human heart and leg. The heart primarily consumed fatty acids and, unexpectedly, little glucose; secreted glutamine and other nitrogen-rich amino acids, indicating active protein breakdown, at a rate ~10 times that of the leg; and released intermediates of the tricarboxylic acid cycle, balancing anaplerosis from amino acid breakdown. Both heart and leg consumed ketones, glutamate, and acetate in direct proportionality to circulating levels, indicating that availability is a key driver for consumption of these substrates. The failing heart consumed more ketones and lactate and had higher rates of proteolysis. These data provide a comprehensive and quantitative picture of human cardiac fuel use.

Figures

Fig. 1.. Human A-V metabolomics reveal distinct… — **Fig. 1.. Human A-V metabolomics reveal distinct fuel profiles of the heart and leg.**
(A) Blood was sampled simultaneously from the radial artery (A), coronary sinus (CS), and femoral vein (FV), and metabolite uptake or release was determined. (B and C) Volcano plot of metabolite abundance in the FV (B) or CS (C) relative to (A). P values were derived from one-sample Wilcoxon test and then Benjamini-Hochberg corrected (P*). Dotted line indicates P* = 0.05. (D and E) Net A-V carbon balance across the leg (D) and heart (E) shown in order of greatest to least average absolute carbon uptake or release.

Fig. 2.. Cardiac nitrogen release reveals net… — **Fig. 2.. Cardiac nitrogen release reveals net amino acid liberation from proteolysis.**
(A) Calculated cardiac sources of free amino acids (uptake from circulation is shown in red, liberation from proteolysis in gray) and released amino acids (shown in blue). Shading is proportional to the quantity of amino acid uptake of secretion. (B) Calculated anaplerotic carbon input from amino acid consumption exceeds carbon released as TCA cycle intermediates. Anaplerotic contribution from lactate through pyruvate carboxylase (PC) could not be determined (dashed lines). All numbers are micromoles of carbon. Non-anaplerotic amino acids (leucine) and amino acids not catabolized in heart (histidine, phenylalanine, and tyrosine) were excluded. PDH, pyruvate dehydrogenase.

Fig. 3.. Comparison of myocardial substrate use… — **Fig. 3.. Comparison of myocardial substrate use in patients with preserved versus reduced ejection fraction.**
(A) Calculated substrate-specific contribution to total cardiac oxygen consumption. Average measured myocardial O2 consumption (ΔO2) is indicated above each bar. (B) Substrate-specific contribution to cardiac ATP generation in patients with preserved ejection fraction (pEF) versus reduced ejection fraction (rEF). (C) Proportion of total ΔO2 accounted for by the catabolism of each indicated substrate class in pEF versus rEF. (D) Net amino acid–derived nitrogen release in patients with pEF versus rEF. *P < 0.05 by t test.

Fig. 4.. Cardiac uptake of acetate, ketones,… — **Fig. 4.. Cardiac uptake of acetate, ketones, and glutamate primarily depends upon circulating concentrations in pEF and rEF.**
(A) Relationship of A-V metabolite gradient (CV – CA) with arterial concentration of indicated metabolites by linear regression. (B) CA versus uptake of indicated metabolites by the heart after adjustment for acetate extraction [(CCS – CA)scaled; see the supplementary data]. *P < 0.05 by analysis of covariance. (C) CA versus uptake of the indicated metabolites by the leg.

References

1. Allard MF, Schönekess BO, Henning SL, English DR, Lopaschuk GD, Am. J. Physiol 267, H742–H750 (1994).
1. Neubauer S, Engl N. J. Med 356, 1140–1151 (2007).
1. Ivanisevic J. et al., Sci. Rep 5, 12757 (2015).
1. Mizuno Y. et al., Metabolism 77, 65–72 (2017).
1. Wisneski JA et al., J. Clin. Invest. 76, 1819–1827 (1985).
1. Wishart DS et al., Nucleic Acids Res. 46 (D1), D608–D617 (2018).
1. Peterson LR et al., Diabetes 57, 32–40 (2008).
1. Hutchins GD et al., J. Am. Coll. Cardiol 15, 1032–1042 (1990).
1. Nelson RH, Prasad A, Lerman A, Miles JM, Diabetes 56, 527–530 (2007).
1. Perry RJ et al., Nature 534, 213–217 (2016).
1. Soliman ML, Rosenberger TA, Mol. Cell. Biochem 352, 173–180 (2011).
1. Taylor PB, Liew CC, Basic Res. Cardiol 71, 27–35 (1976).
1. Peuhkurinen KJ, Hassinen IE, Biochem. J 202, 67–76 (1982).
1. Takala T, Hiltunen JK, Hassinen IE, Biochem. J 192, 285–295 (1980).
1. Taegtmeyer H, Ferguson AG, Lesch M, Exp. Mol. Pathol 26, 52–62 (1977).
1. Pisarenko OI, Solomatina ES, Studneva IM, Biochim. Biophys. Acta 885, 154–161 (1986).
1. Clowes GHA Jr., Randall HT, Cha C-J, JPEN J. Parenter. Enteral Nutr 4, 195–205 (1980).
1. Preedy VR, Paska L, Sugden PH, Schofield PS,Sugden MC, Biochem. J 250, 179–188 (1988).
1. Sun H. et al., Circulation 133, 2038–2049 (2016).
1. Li T. et al., Cell Metab. 25, 374–385 (2017).
1. Wang W. et al., Am. J. Physiol. Heart Circ. Physiol 311, H1160–H1169 (2016).
1. Neinast MD et al., Cell Metab. 29, 417–429.e4 (2019).
1. Garry DJ et al., Nature 395, 905–908 (1998).
1. Romero-Herrera AE, Lehmann H, Proc. R. Soc. London Ser. B 186, 249–279 (1974).
1. Commisso C. et al., Nature 497, 633–637 (2013).
1. Garland PB, Randle PJ, Newsholme EA, Nature 200, 169–170 (1963).
1. Comte B. et al., J. Biol. Chem 272, 26125–26131 (1997).
1. Panchal AR et al., Am. J. Physiol. Heart Circ. Physiol 279, H2390–H2398 (2000).
1. Noh H-L, Okajima K, Molkentin JD, Homma S,Goldberg IJ, Am. J. Physiol. Endocrinol. Metab. 291, E755–E760 (2006).
1. Banke NH et al., Circ. Res 107, 233–241 (2010).
1. Xia Y, Zweier JL, J. Biol. Chem 270, 18797–18803 (1995).
1. Laughlin MR, Petit WA Jr., Shulman RG, Barrett EJ,Am. J. Physiol 258, E184–E190 (1990).
1. Schneider CA, Taegtmeyer H, Circ. Res 68, 1045–1050 (1991).
1. Evans G, Physiol J. 82, 468–480 (1934).
1. Ahmad T. et al., J. Am. Coll. Cardiol 67, 291–299 (2016).
1. Hunter WG et al., J. Am. Heart Assoc 5, e003190 (2016).
1. Bedi KC Jr. et al., Circulation 133, 706–716 (2016).
1. Nielsen R. et al., Circulation 139, 2129–2141 (2019).

Source: PubMed

Comprehensive quantification of fuel use by the failing and nonfailing human heart

Abstract

Figures

References

赞助者和合作者

医疗条件

药物干预